Last updated: September 1, 2026
The acetaminophen, caffeine, and dihydrocodeine bitartrate combination is a mature prescription analgesic marketed in the United States under Trezix and through generic or authorized-generic channels. Its commercial profile is constrained by opioid scheduling, abuse-deterrence concerns, generic competition, limited public disclosure of brand revenue, and the availability of non-opioid and triptan-based migraine treatments. The product has residual value in acute migraine and tension-type headache treatment, but its financial trajectory is more consistent with a declining or low-growth specialty-generic asset than with a protected branded pharmaceutical franchise.
What is the acetaminophen, caffeine, and dihydrocodeine combination?
The U.S. product is Trezix, an oral capsule containing:
| Component |
Amount per capsule |
Pharmacologic role |
| Acetaminophen |
325 mg |
Non-opioid analgesic |
| Caffeine |
30 mg |
Analgesic adjuvant |
| Dihydrocodeine bitartrate |
16 mg |
Opioid analgesic |
Trezix is indicated for the management of acute pain severe enough to require an opioid analgesic when alternative treatments are inadequate. The product is also used in clinical practice for acute migraine and severe headache, although its opioid component limits its position in modern migraine-treatment algorithms. The FDA-approved labeling identifies the product as a Schedule II controlled substance because of dihydrocodeine [1].
The combination differs from Fioricet, which contains acetaminophen, butalbital, and caffeine, and from Synalgos-DC, which contains aspirin, caffeine, and dihydrocodeine. Trezix does not contain aspirin, reducing aspirin-related gastrointestinal and platelet-inhibition concerns, but it retains the risks associated with acetaminophen exposure and opioid dependence.
What FDA regulatory status does Trezix have?
Trezix is an FDA-approved prescription drug marketed as an immediate-release capsule. The FDA label contains boxed warnings covering opioid-related risks, including addiction, abuse, misuse, life-threatening respiratory depression, accidental ingestion, neonatal opioid withdrawal syndrome, and interactions with benzodiazepines or other central nervous system depressants [1].
Key regulatory characteristics include:
| Regulatory attribute |
Status |
| Dosage form |
Immediate-release capsule |
| Route |
Oral |
| Prescription status |
Prescription-only |
| Controlled-substance status |
Schedule II |
| Active opioid |
Dihydrocodeine bitartrate |
| Acetaminophen exposure risk |
Yes |
| FDA approval pathway |
New drug application product |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
Abbreviated new drug application, where applicable |
The product is subject to opioid prescribing controls, state-level prescribing restrictions, prescription-monitoring requirements, and postmarketing pharmacovigilance. These controls raise the commercial burden for manufacturers and distributors relative to non-controlled analgesics.
What patents protect acetaminophen, caffeine, and dihydrocodeine bitartrate products?
The core active-ingredient combination is not a new molecular entity. Acetaminophen, caffeine, and dihydrocodeine have long-established use histories, and the commercial product does not depend on a conventional composition-of-matter patent estate.
| Protection category |
Commercial relevance |
| Active-ingredient patents |
Effectively expired or unavailable for the mature ingredients |
| Combination patent |
Limited value unless supported by a novel formulation or clinical-use claim |
| Formulation patents |
Potentially relevant but not a primary barrier in the standard immediate-release product |
| Method-of-use patents |
Possible in theory, but likely narrow and difficult to enforce against routine prescribing |
| Manufacturing patents |
Low strategic importance for a conventional oral capsule |
| Regulatory exclusivity |
No meaningful new-drug exclusivity expected for the mature product |
| Biosimilar exclusivity |
Not applicable |
The principal commercial protection is therefore regulatory compliance, distribution access, prescriber familiarity, controlled-substance infrastructure, and any product-specific marketing rights rather than a durable patent moat. Patent expiry does not create a single identifiable loss-of-exclusivity event because the active ingredients and conventional dosage form have been genericized for many years.
When does this product lose exclusivity?
The combination has already passed the principal exclusivity phase associated with innovative pharmaceutical products. There is no credible basis for assigning a future composition-of-matter patent expiry date to the standard product.
The more relevant commercial timeline is:
| Period |
Market event |
Financial effect |
| Historical period |
Development and approval of opioid-containing analgesic combinations |
Initial branded pricing opportunity |
| Generic-entry period |
Emergence of competing prescription products and pharmacy substitution |
Price compression |
| Current period |
Controlled-substance restrictions and mature therapeutic class |
Lower volume and limited pricing power |
| Future period |
Continued generic supply, opioid stewardship, and non-opioid substitution |
Ongoing revenue pressure |
Any remaining exclusivity would have to arise from a specific formulation patent, trademark, private distribution agreement, or commercial arrangement. It would not arise from the age of the active ingredients themselves.
What is the Orange Book status of Trezix?
The FDA Orange Book is the principal source for determining whether an approved drug has listed patents and whether an authorized generic or abbreviated new drug application may rely on the reference product’s approval [2].
For Trezix, the relevant diligence issue is whether the reference listing carries currently enforceable patents or exclusivity codes. A mature immediate-release combination product generally has limited Orange Book leverage unless its sponsor has listed a formulation, delivery, or use patent that satisfies FDA listing requirements.
The commercial implications are:
- A lack of active Orange Book patents lowers the cost of generic entry.
- Paragraph IV litigation is less likely where no relevant patent is listed.
- Generic applicants can generally rely on an ANDA pathway rather than conducting a full clinical development program.
- Any litigation risk would depend on product-specific listings and the asserted scope of the claims.
An Orange Book review should distinguish the reference NDA from other products containing dihydrocodeine, caffeine, or acetaminophen. Synalgos-DC and Trezix are separate products with different active ingredients and cannot be treated as interchangeable patent records.
Are Paragraph IV challenges likely for this combination?
Paragraph IV risk is structurally low for the mature combination but is not zero. A generic applicant could challenge a listed patent by asserting that the patent is invalid, unenforceable, or not infringed. The absence of a valuable composition-of-matter patent makes a high-value patent challenge less likely than in protected branded medicines.
Potential Paragraph IV targets would include:
- A novel dosage-form patent.
- A capsule-composition claim.
- A method-of-use claim directed to a defined headache population.
- A manufacturing claim that materially limits generic production.
- A patent covering a specific ratio or release profile.
The economic incentive to litigate is limited because the market is likely small relative to major opioid analgesics, migraine medicines, or blockbuster combination products. A first-filer could obtain 180-day generic exclusivity under the Hatch-Waxman framework, but the expected prize depends on prescription volume and the number of potential competitors [3].
What formulations are protected by the product’s intellectual property?
The commercially relevant formulation is a conventional immediate-release capsule. Its technical design does not appear to depend on an advanced delivery system such as extended release, transdermal delivery, abuse-deterrent technology, or a long-acting injectable platform.
Immediate-release capsule
The standard formulation has several commercial advantages:
- Low manufacturing complexity.
- Established raw-material supply.
- Conventional oral administration.
- Straightforward ANDA development.
- Limited formulation differentiation.
Its disadvantages are equally clear. A conventional capsule is easier to copy, has limited ability to command a premium, and does not provide a strong regulatory basis for blocking generic substitution.
Abuse-deterrence considerations
Dihydrocodeine is an opioid and can be misused. Trezix is not generally positioned as an abuse-deterrent formulation. The product therefore competes under the ordinary regulatory and risk-management framework for immediate-release opioid medicines rather than benefiting from a proprietary abuse-deterrent platform.
Acetaminophen toxicity management
The product also carries cumulative acetaminophen risk. The FDA has emphasized the danger of severe liver injury from excessive acetaminophen exposure, particularly when patients combine prescription products with over-the-counter acetaminophen-containing medicines [4]. This risk can reduce prescribing in patients with liver disease, alcohol-use concerns, polypharmacy, or uncertain medication histories.
How large is the market for acetaminophen, caffeine, and dihydrocodeine?
No reliable public source provides a standalone global market-size or revenue series for the exact three-ingredient combination. Public company filings generally aggregate the product with broader analgesic, specialty-pharmaceutical, or generic portfolios.
The market is best characterized as a narrow prescription segment with the following demand drivers:
| Demand driver |
Effect on volume |
| Acute severe headache and migraine prescribing |
Supports demand |
| Established physician familiarity |
Supports persistence |
| Opioid prescribing restrictions |
Reduces demand |
| Non-opioid migraine therapies |
Reduces substitution opportunity |
| Generic substitution |
Reduces price |
| Patient need for rapid oral analgesia |
Supports episodic use |
| Controlled-substance monitoring |
Increases prescribing friction |
| Acetaminophen safety concerns |
Limits use in selected patients |
The addressable market is narrower than the overall acetaminophen market, the overall caffeine-containing analgesic market, or the opioid analgesic market. Those broader markets should not be used as proxies for the revenue opportunity of the specific combination.
What is the financial trajectory of the product?
The likely financial trajectory is mature, low-growth, and price-sensitive. Standalone product revenue is not publicly reported with sufficient consistency to establish a verified annual sales history for Trezix or the exact generic combination.
Revenue trajectory
| Financial factor |
Expected direction |
| Unit demand |
Flat to declining |
| Net price |
Declining under generic pressure |
| Gross margin |
Variable; vulnerable to commodity and compliance costs |
| Promotional spending |
Limited relative to major branded medicines |
| Market access |
Dependent on controlled-substance distribution |
| Product life-cycle value |
Residual and niche |
| Peak-sales recovery potential |
Low without reformulation or new indication |
A branded supplier may preserve revenue through higher cash-pay pricing, specialty-pharmacy distribution, limited competition, or physician-directed use. Those mechanisms are weaker than patent exclusivity and can erode quickly when additional generic suppliers enter.
Revenue sensitivity
The product’s financial performance is particularly sensitive to prescription count because pricing power is limited. A simplified revenue model is:
Net revenue = dispensed prescriptions × units per prescription × net price per unit
A 10% decline in prescriptions combined with a 5% decline in net price produces an approximately 14.5% decline in revenue before mix effects. For a mature genericized product, volume erosion and price erosion can occur simultaneously.
Which companies compete with Trezix?
Competition comes from three groups: direct ingredient substitutes, broader opioid analgesics, and non-opioid migraine or headache treatments.
Direct and near-direct competitors
| Product or class |
Competitive relationship |
| Generic acetaminophen/caffeine/dihydrocodeine |
Direct substitute |
| Synalgos-DC |
Similar dihydrocodeine-caffeine combination, but contains aspirin |
| Fioricet and generic butalbital combinations |
Headache-treatment substitute |
| Codeine-containing analgesics |
Opioid-combination substitute |
| Tramadol products |
Alternative opioid analgesic |
| NSAIDs |
Non-opioid pain alternative |
| Triptans |
Migraine-specific alternative |
| CGRP antagonists |
Newer migraine-specific alternative |
| Gepants and ditans |
Non-opioid acute migraine options |
Nurtec ODT, Ubrelvy, Zavzpret, Reyvow, and triptan products compete for acute migraine treatment where the prescriber prioritizes migraine-specific efficacy or avoidance of opioid exposure. Their commercial positioning is different, but they can reduce the pool of patients eligible for an opioid-containing combination.
How does Trezix compare with Synalgos-DC and Fioricet?
| Attribute |
Trezix |
Synalgos-DC |
Fioricet |
| Acetaminophen |
Yes |
No |
Yes |
| Aspirin |
No |
Yes |
No |
| Caffeine |
Yes |
Yes |
Yes |
| Opioid |
Dihydrocodeine |
Dihydrocodeine |
No |
| Barbiturate |
No |
No |
Butalbital |
| Main commercial use |
Acute pain and headache |
Pain and headache |
Tension headache |
| Key safety concern |
Opioid dependence and acetaminophen toxicity |
Opioid, aspirin, and bleeding risks |
Barbiturate dependence and acetaminophen toxicity |
| Generic substitution pressure |
High |
High |
High |
| Patent strength |
Low for mature formulation |
Low for mature formulation |
Low for mature formulation |
Trezix has a potential tolerability advantage over Synalgos-DC for patients in whom aspirin is unsuitable. It has a potential safety disadvantage relative to non-opioid headache medicines because it combines an opioid with acetaminophen.
What litigation and settlement risks affect the product?
No high-value, product-specific patent litigation or settlement framework defines the market in the way that patent settlements shape major branded drugs. The more material legal risks arise from opioid distribution, marketing, prescribing, labeling, and compliance.
Relevant risk areas include:
- Controlled-substance distribution compliance.
- Diversion and suspicious-order monitoring.
- False or misleading promotional claims.
- Failure to communicate opioid risks.
- State opioid litigation and settlement exposure.
- Product-liability claims involving overdose, dependence, or liver injury.
- Contract disputes involving specialty distributors or authorized generics.
Patent litigation would become commercially important only if a sponsor asserted a live formulation or use patent against a generic applicant. Without such a patent, litigation is unlikely to produce a durable market exclusion.
What generic launch scenarios exist?
Scenario 1: Continued mature generic supply
This is the base case. Multiple suppliers compete on price, pharmacy access, and wholesaler availability. Revenue declines gradually, while shortages or supplier exits may cause temporary price increases.
Scenario 2: Single- or limited-source supply
If only one or two manufacturers remain active, the market may experience higher prices and intermittent supply constraints. This can improve short-term supplier economics but increases regulatory and reputational scrutiny.
Scenario 3: Additional ANDA entry
New entrants would likely reduce average selling prices and compress branded share. A Paragraph IV certification would create litigation only if an active Orange Book patent exists.
Scenario 4: Branded reformulation
A sponsor could attempt to improve commercial durability through an abuse-deterrent formulation, an alternative dosage form, or a new fixed-dose ratio. This would require meaningful clinical, regulatory, manufacturing, and reimbursement investment. The return would be uncertain because physicians increasingly limit opioid use for headache disorders.
Scenario 5: Therapeutic substitution
Patients may move to NSAIDs, triptans, gepants, or other non-opioid therapies. This is the most persistent long-term risk to demand.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate operationally but low technologically. A supplier must meet requirements for:
- Controlled-substance handling and security.
- Qualified active pharmaceutical ingredient sourcing.
- Content uniformity for three active ingredients.
- Acetaminophen impurity and degradation control.
- Caffeine and opioid assay consistency.
- Capsule filling and packaging controls.
- DEA registration and quota compliance.
- Serialization and supply-chain traceability.
These requirements can limit the number of reliable suppliers, but they do not create a durable patent barrier. The active ingredients are established, the dosage form is conventional, and the technical process is unlikely to require specialized equipment beyond standard solid-dose manufacturing.
What geographic markets offer the greatest opportunity?
The United States is the most commercially relevant market because Trezix is an established U.S. prescription product and dihydrocodeine has a recognizable regulatory pathway there. Expansion outside the United States is constrained by:
- Different controlled-substance classifications.
- Country-specific opioid prescribing rules.
- National reimbursement controls.
- Local registration requirements.
- Different treatment standards for migraine and acute pain.
- Limited commercial value of a mature combination product.
Geographic expansion would therefore be more likely through licensing or local generic registration than through a global branded launch.
What licensing deals could affect the asset?
Licensing value is limited but may exist in four structures:
- An authorized-generic agreement between the reference-product sponsor and a generic manufacturer.
- A specialty-pharmacy distribution agreement.
- A regional commercialization license.
- A formulation-development partnership for an abuse-deterrent or non-opioid version.
A licensing transaction would likely be valued on current cash flow, supply continuity, regulatory infrastructure, and distribution rights rather than on patent duration. Royalty economics would be difficult to support unless the licensor controls a scarce supply source or owns a defensible formulation.
How strong is the patent estate for acetaminophen, caffeine, and dihydrocodeine?
The patent estate is weak for the standard immediate-release combination.
| Patent-strength dimension |
Assessment |
| Composition of matter |
Very weak |
| Standard formulation |
Weak |
| Method of use |
Potentially narrow |
| Manufacturing process |
Low-to-moderate operational value |
| Regulatory exclusivity |
Minimal |
| Brand and distribution rights |
Potentially useful but non-patent based |
| Generic-entry resistance |
Low |
| Long-term pricing power |
Low |
The strongest remaining commercial protections are likely to be contractual and operational. They include distribution relationships, manufacturing capacity, controlled-substance compliance systems, and pharmacy or prescriber familiarity.
Key Takeaways
- Acetaminophen, caffeine, and dihydrocodeine bitartrate is a mature prescription analgesic combination marketed in the United States as Trezix.
- The standard product has no meaningful new-molecular-entity patent protection.
- The immediate-release capsule is technically straightforward and vulnerable to generic substitution.
- Standalone revenue for Trezix and the exact combination is not publicly disclosed in a consistent, auditable series.
- The financial trajectory is likely flat to declining, with pressure from generic pricing, opioid restrictions, and non-opioid migraine treatments.
- Paragraph IV litigation risk is low unless a live formulation or method-of-use patent is listed.
- The main legal risks are controlled-substance compliance, opioid marketing, product liability, and distribution oversight.
- The product’s residual value depends on supply reliability, niche prescribing, distribution access, and any authorized-generic or specialty-pharmacy arrangements.
FAQs
Is Trezix still commercially available?
Trezix has been marketed as a prescription capsule in the United States, but availability can vary by manufacturer, distributor, pharmacy, and controlled-substance supply conditions.
Is acetaminophen, caffeine, and dihydrocodeine a generic drug?
The active ingredients are mature, and generic versions may be available through ANDA-approved products or equivalent market channels. Product-specific availability and substitutability depend on FDA approval records and pharmacy inventory.
Is Trezix stronger than codeine-acetaminophen?
Dihydrocodeine and codeine differ in potency, metabolism, formulation, and patient response. Direct strength comparisons are clinically inappropriate without considering dose, indication, opioid tolerance, and prescribing information.
Can this combination be used for migraine?
It may be prescribed for acute pain or headache, but opioid-containing products are generally used cautiously because of dependence, medication-overuse headache, and safety concerns. Migraine-specific non-opioid therapies are important competitors.
Does the product have biosimilar competition?
No. Biosimilars apply to biological products. Trezix and related acetaminophen, caffeine, and dihydrocodeine products are chemically synthesized small-molecule medicines and compete through generic-drug pathways.
References
- U.S. Food and Drug Administration. (2024). Trezix prescribing information. FDA. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2023). Abbreviated new drug application approvals and 180-day generic drug exclusivity. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
- U.S. Food and Drug Administration. (2011). Prescription combination drug products with more than 325 mg of acetaminophen. FDA. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-prescription-acetaminophen-products-be-limited-325-mg-dosage-unit
